Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Piketty

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
AIDS (London, England)|June 10, 1998
Discrepant responses to triple combination antiretroviral therapy in advanced HIV diseaseC Piketty, P Castiel, L Belec, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2009
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trialY Yazdanpanah, C Fagard, D Descamps, et al.
Clinical Endocrinology|October 9, 2001
Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV diseaseC Piketty, D Jayle, A Leplege, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B studyJ I Silverberg, A Pinter, A Alavi, et al.
The British Journal of Dermatology|March 15, 2019
Most associations of early-life environmental exposures and genetic risk factors poorly differentiate between eczema phenotypes: the Generation R StudyC Hu, L Duijts, N S Erler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2004
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trialO Launay, L Roudière, N Boukli, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
AIDS (London, England)|June 10, 1998
Discrepant responses to triple combination antiretroviral therapy in advanced HIV diseaseC Piketty, P Castiel, L Belec, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2009
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trialY Yazdanpanah, C Fagard, D Descamps, et al.
Clinical Endocrinology|October 9, 2001
Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV diseaseC Piketty, D Jayle, A Leplege, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B studyJ I Silverberg, A Pinter, A Alavi, et al.
The British Journal of Dermatology|March 15, 2019
Most associations of early-life environmental exposures and genetic risk factors poorly differentiate between eczema phenotypes: the Generation R StudyC Hu, L Duijts, N S Erler, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 20, 2004
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trialO Launay, L Roudière, N Boukli, et al.
Pageof 6